Mr. Yanling Cao is a founding member and Managing Director of Boyu Capital and in charge of investments and portfolio management in the healthcare sector. He currently serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Prior to Boyu, Mr. Cao worked as an investment professional at General Atlantic and Goldman Sachs on a wide range of strategic and financial transactions. Mr. Cao received Bachelor of Arts in Economics and Mathematics, summa cum laude, from Middlebury College.
BOARD OF DIRECTORS
Mr. Edward Hu is Co-Chief Executive Officer at WuXi AppTec. Mr. Hu manages WuXi AppTec’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. Mr. Hu previously served as WuXi’s chief operating officer and chief financial officer for five years until April 2014. Prior to joining WuXi in August 2007, he was a senior vice president and chief operating officer at Tanox, a biopharmaceutical company acquired by Genentech. He also held positions at Merck & Co., Inc. as a senior financial analyst and later in business and financial planning at Biogen, Inc. Mr. Hu completed his Ph.D. work, all but dissertation, in biophysics and biochemistry at Carnegie Mellon University, where he also received his M.B.A.
Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers also serves on the Board of Directors for G1 Therapeutics (GTHX), Corvidia Therapeutics and Armaron Bio Ltd and as a Board observer for several private companies.
Pascal is Executive Director and Chief Executive Officer of AstraZeneca. He brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organization. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.
Mr. Sean Tong is co-founder and Managing Partner of Boyu Capital and currently serves on the board of a number of publicly listed and privately held companies. Prior to Boyu, he was a Managing Director and Head of Greater China at General Atlantic LLC and Providence Equity Partners. He graduated magna cum laude from Harvard University.
Dr. Vincent Xiang is a managing director at Hillhouse Capital, responsible for its global bioventure investments. He was a partner at 6 Dimensions Capital. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group, led the $550M acquisition of US Epic Pharma in 2016. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, and Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages.
Dr. Bing Yao is the Executive Chairman and CEO of Viela Bio. Bing brings more than 20 years’ experience in the biopharmaceutical industry, with a track record of leading successful discovery and development of multiple biotherapeutics. Most recently, during his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Bing is on the Board of Directors for NexImmune. Bing received his Ph.D in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.